Article

Protease-Activated Receptor 2 and Its Role in the Progression from Metabolic-Disfunction Associated Steatotic Liver Disease to Hepatocellular Carcinoma

2025-06-19

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently emerged as the predominant aetiology of chronic liver disease worldwide. This condition can progress to hepatocellular carcinoma (HCC) through various pathogenetic mechanisms. Briefly, metabolic dysfunction, which may occur in genetically susceptible individuals, disrupts lipid metabolism homeostasis. This imbalance leads to increased ox...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 31076335-c461-5537-a32f-efdceb7249f0
DOI: 10.20944/preprints202506.1630.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Protease-Activated Receptor 2 and Its Role in the Progression from Metabolic-Disfunction Associated Steatotic Liver Disease to Hepatocellular CarcinomaDOI 10.20944/preprints202506.1630.v1Read

Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.Semantic proximity Read

Lp-Pla2 As A Biomarker and Its Possible Associations with Sars-Cov-2 InfectionSemantic proximity Read

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.Semantic proximity Read

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read

Innate Immune Receptors: Key Regulators of Metabolic Disease ProgressionSemantic proximity Read

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologiesSemantic proximity Read

MicroRNAs in metabolic dysfunction‐associated diseases: Pathogenesis and therapeutic opportunitiesSemantic proximity Read

Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity.Semantic proximity Read

Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and CancerSemantic proximity Read

Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 OutcomesSemantic proximity Read

Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.Semantic proximity Read